Back to public companies

HYFT Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

MindWalk Holdings Corp | Needs refresh | Last updated: 2026-03-29T08:34:16Z

TickerHYFT
Market Cap50.0M
Cash RunwayRunway > 12 months
Next Catalystn/a

Public Research Snapshot

MindWalk Holdings Corp is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for All-in-one biointelligence ecosystem in therapeutic and anti-drug antibodies, diagnostics, vaccines, and peptide therapeutics using Peptide.

Pipeline

AssetIndicationModalityStagePublic Note
All-in-one biointelligence ecosystemtherapeutic and anti-drug antibodies, diagnostics, vaccines, and peptide therapeuticsPeptiden/aPublic pipeline row
Dengue vaccinen/aVaccinen/aPublic pipeline row
What people are sayingn/aAntibodyPivotalPublic pipeline row
Customizable BioIntelligence Ecosystemantibodies, peptide therapeutics and vaccinesPeptiden/aPublic pipeline row
Advanced Lab Researchn/aAntibodyn/aPublic pipeline row
Bio-Native AIn/aAntibodyn/aPublic pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

  • No public filing rows are loaded yet.

Clinical Trial Activity

NCT IDPhaseStatusEnrollmentPrimary Completion
No public trial rows are loaded yet.

Scientific Context

  • clinical_stage | pivotal
  • clinical_stage | pivotal
  • combination_strategy | combined with integrated biological data and insights, supports stronger starts, deeper context, and more informed progression toward
  • combination_strategy | combined with integrated biological data and insights, supports stronger starts, deeper context, and more informed progression toward
  • indication | the Bispecific and Cell Therapy Era MindWalk Applies HYFT

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.